BioCentury
ARTICLE | Finance

Enterprise engages

Why VCs believe Enterprise can improve on existing respiratory therapies

April 12, 2018 8:13 AM UTC

Enterprise Therapeutics Ltd.’s belief that it can improve on existing mucus-clearing therapies led an investor syndicate to back the respiratory company in a £29 million ($40.9 million) series B round.

Versant Ventures and Novartis Venture Fund led the financing, which also included fellow new investor Forbion and existing investors Epidarex Capital and IP Group...